Biological Therapy in Treating Patients With Myelodysplastic Syndrome
Leukemia, Myelodysplastic Syndromes
About this trial
This is an interventional treatment trial for Leukemia focused on measuring refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, de novo myelodysplastic syndromes, previously treated myelodysplastic syndromes, secondary myelodysplastic syndromes, refractory cytopenia with multilineage dysplasia, childhood myelodysplastic syndromes
Eligibility Criteria
DISEASE CHARACTERISTICS: Diagnosis of myelodysplastic syndrome with no greater than 20% marrow blasts with: Single or multilineage cytopenia (neutrophils less than 2,000/mm^3 and/or platelet count less than 100,000/mm^3 and/or reticulocyte count less than 18,000/mm^3) OR Transfusion requirement of at least 2 units packed red blood cells per month and one of the following: Suitable marrow donor unavailable Ineligible for a transplantation protocol Unwilling to proceed with transplantation No chronic myelomonocytic leukemia PATIENT CHARACTERISTICS: Age: Any age Performance status: Not specified Life expectancy: Not specified Hematopoietic: See Disease Characteristics Hepatic: Not specified Renal: Not specified Other: No other severe disease that would preclude study No active severe infection (e.g., pneumonia or septicemia) or severe infections within the past 2 weeks PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics At least 4 weeks since prior hematopoietic growth factors No concurrent hematopoietic growth factors Chemotherapy: At least 4 weeks since prior cytotoxic therapy No concurrent cytotoxic therapy Endocrine therapy: Not specified Radiation therapy: Not specified Surgery: Not specified Other: At least 4 weeks since prior immunomodulatory therapy No concurrent immunomodulatory therapy
Sites / Locations
- Fred Hutchinson Cancer Research Center